Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q4 2022 vs. Q3 2022

How the institutions holding Landos Biopharma, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of LABP: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders3123−8
Shares21.6M15.7M−5.86M (−27.1%)
Value$14.0M$7.87M−$6.17M (−43.9%)

New holders (4)

Institutions that held Landos Biopharma, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to LABP in Q4 2022
InstitutionSharesValue% of portfolio
HRT Financial LP52,564$26.0K0.00%
Susquehanna International Group, LLP21,064$10.5K0.00%
Jane Street Group, LLC14,826$7.41K0.00%
UBS Group AG375$1880.00%

Sold out (12)

Institutions that held Landos Biopharma, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of LABP in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
RTW Investments, LP3,975,722$2.58M
OUP Management Co., LLC1,237,667$804.0K
Botty Investors LLC127,262$83.0K
Two Sigma Investments, LP19,420$13.0K
Two Sigma Advisers, LP19,800$13.0K
Bank of America Corp16,482$11.0K
Balyasny Asset Management LLC15,687$10.0K
Goldman Sachs Group Inc13,092$9.00K
Man Group plc14,387$9.00K
Stratos Wealth Partners, LTD.10,000$7.00K
BNP Paribas Arbitrage, SA1,122$729
China Universal Asset Management Co., Ltd.377$0